The Pennant Group (PNTG) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.36
- Estimate
- $0.33
- Surprise
- +9.1%
- Revenue (period 2026-06-30)
- $298.0M
- Score today
- 5.4/10
Revenue source: xbrl.
How the report landed
The Pennant Group (PNTG) beat the $0.33 estimate with diluted EPS of $0.36 — a clear 9.1% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PNTG Sell at 5.4/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +9.1% surprise compares with a +6.6% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Regulatory: government payors (Medicare and Medicaid) (61.5%)
- Concentration risk — Regulatory: Medicare (hospice services) (87.0%)
- Quality below floor (3.0 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $39.20
- Price target
- $40.60
- Stop
- $36.68
- Upside to target
- +3.6%
- Reward-to-risk
- 0.5:1
The stock trades at 43.1× trailing but 24.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
PNTG at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Care Facilities
- Market cap
- $1.37B
- P/E (fwd)
- 24.7
- P/E (ttm)
- 43.1
- 52-week range
- $22.25–$42.69
- Off 52-week high
- 8.2%
- RSI (14)
- 52
- Volume vs avg
- 1.28×
- Score today
- 5.4/10